113 related articles for article (PubMed ID: 18339636)
21. Improved lipid profiles and maintenance of virologic control in heavily pretreated HIV-infected patients who switched from stavudine to tenofovir treatment.
Schewe CK; Maserati R; Wassmer G; Adam A; Weitner L
Clin Infect Dis; 2006 Jan; 42(1):145-7. PubMed ID: 16323105
[TBL] [Abstract][Full Text] [Related]
22. A randomized, placebo-controlled trial of rosiglitazone for HIV-related lipoatrophy.
Cavalcanti RB; Raboud J; Shen S; Kain KC; Cheung A; Walmsley S
J Infect Dis; 2007 Jun; 195(12):1754-61. PubMed ID: 17492590
[TBL] [Abstract][Full Text] [Related]
23. Mitochondrial effects of antiretroviral therapies in asymptomatic patients.
López S; Miró O; Martínez E; Pedrol E; Rodríguez-Santiago B; Milinkovic A; Soler A; García-Viejo MA; Nunes V; Casademont J; Gatell JM; Cardellach F
Antivir Ther; 2004 Feb; 9(1):47-55. PubMed ID: 15040536
[TBL] [Abstract][Full Text] [Related]
24. Contribution of mitochondrial dysfunction and oxidative stress to cellular premature senescence induced by antiretroviral thymidine analogues.
Caron M; Auclairt M; Vissian A; Vigouroux C; Capeau J
Antivir Ther; 2008; 13(1):27-38. PubMed ID: 18389896
[TBL] [Abstract][Full Text] [Related]
25. Improvements in cheek volume in lipoatrophic individuals switching away from thymidine nucleoside reverse transcriptase inhibitors.
Benn P; Sauret-Jackson V; Cartledge J; Ruff C; Sabin CA; Moyle G; Linney A; Reilly G; Edwards SG
HIV Med; 2009 Jul; 10(6):351-5. PubMed ID: 19490181
[TBL] [Abstract][Full Text] [Related]
26. Mitochondrial toxicity of nucleoside analogues in primary human lymphocytes.
Setzer B; Schlesier M; Thomas AK; Walker UA
Antivir Ther; 2005; 10(2):327-34. PubMed ID: 15865227
[TBL] [Abstract][Full Text] [Related]
27. In vitro analysis of synergism and antagonism of different nucleoside/nucleotide analogue combinations on the inhibition of human immunodeficiency virus type 1 replication.
Perez-Olmeda M; Garcia-Perez J; Mateos E; Spijkers S; Ayerbe MC; Carcas A; Alcami J
J Med Virol; 2009 Feb; 81(2):211-6. PubMed ID: 19107982
[TBL] [Abstract][Full Text] [Related]
28. Relative mutagenic potencies of several nucleoside analogs, alone or in drug pairs, at the HPRT and TK loci of human TK6 lymphoblastoid cells.
Carter MM; Torres SM; Cook DL; McCash CL; Yu M; Walker VE; Walker DM
Environ Mol Mutagen; 2007; 48(3-4):239-47. PubMed ID: 17358029
[TBL] [Abstract][Full Text] [Related]
29. Mitochondrial toxicity of indinavir, stavudine and zidovudine involves multiple cellular targets in white and brown adipocytes.
Viengchareun S; Caron M; Auclair M; Kim MJ; Frachon P; Capeau J; Lombès M; Lombès A
Antivir Ther; 2007; 12(6):919-29. PubMed ID: 17926646
[TBL] [Abstract][Full Text] [Related]
30. Glucose metabolism, lipid, and body fat changes in antiretroviral-naive subjects randomized to nelfinavir or efavirenz plus dual nucleosides.
Dubé MP; Parker RA; Tebas P; Grinspoon SK; Zackin RA; Robbins GK; Roubenoff R; Shafer RW; Wininger DA; Meyer WA; Snyder SW; Mulligan K
AIDS; 2005 Nov; 19(16):1807-18. PubMed ID: 16227788
[TBL] [Abstract][Full Text] [Related]
31. Proximal tubular dysfunction associated with tenofovir and didanosine causing Fanconi syndrome and diabetes insipidus: a report of 3 cases.
Irizarry-Alvarado JM; Dwyer JP; Brumble LM; Alvarez S; Mendez JC
AIDS Read; 2009 Mar; 19(3):114-21. PubMed ID: 19334328
[TBL] [Abstract][Full Text] [Related]
32. Metabolic and anthropometric changes one year after switching from didanosine/stavudine to tenofovir in HIV-infected patients.
Claas GJ; Jülg B; Goebel FD; Bogner J
Eur J Med Res; 2007 Feb; 12(2):54-60. PubMed ID: 17369118
[TBL] [Abstract][Full Text] [Related]
33. Saquinavir exposure in HIV-infected patients with chronic viral hepatitis.
Moltó J; Llibre JM; Ribera E; Mínguez C; del Río JS; Pedrol E; Vallecillo G; Cedeño S; Valle M; Miranda C; Negredo E; Clotet B;
J Antimicrob Chemother; 2009 May; 63(5):992-7. PubMed ID: 19279052
[TBL] [Abstract][Full Text] [Related]
34. The genetic toxicity effects of lamivudine and stavudine antiretroviral agents.
Guimarães NN; de Andrade HH; Lehmann M; Dihl RR; Cunha KS
Expert Opin Drug Saf; 2010 Sep; 9(5):771-81. PubMed ID: 20377473
[TBL] [Abstract][Full Text] [Related]
35. Effect of reducing the dose of stavudine on body composition, bone density, and markers of mitochondrial toxicity in HIV-infected subjects: a randomized, controlled study.
McComsey GA; Lo Re V; O'Riordan M; Walker UA; Lebrecht D; Baron E; Mounzer K; Frank I
Clin Infect Dis; 2008 Apr; 46(8):1290-6. PubMed ID: 18444869
[TBL] [Abstract][Full Text] [Related]
36. Hemochromatosis gene polymorphisms, mitochondrial haplogroups, and peripheral lipoatrophy during antiretroviral therapy.
Hulgan T; Tebas P; Canter JA; Mulligan K; Haas DW; Dubé M; Grinspoon S; Robbins GK; Motsinger AA; Kallianpur AR;
J Infect Dis; 2008 Mar; 197(6):858-66. PubMed ID: 18419350
[TBL] [Abstract][Full Text] [Related]
37. Fanconi syndrome and lactic acidosis associated with stavudine and lamivudine therapy.
Nelson M; Azwa A; Sokwala A; Harania RS; Stebbing J
AIDS; 2008 Jul; 22(11):1374-6. PubMed ID: 18580619
[TBL] [Abstract][Full Text] [Related]
38. Peripheral blood mitochondrial DNA/nuclear DNA (mtDNA/nDNA) ratio as a marker of mitochondrial toxicities of stavudine containing antiretroviral therapy in HIV-infected Malawian patients.
Kampira E; Dzobo K; Kumwenda J; van Oosterhout JJ; Parker MI; Dandara C
OMICS; 2014 Jul; 18(7):438-45. PubMed ID: 24816082
[TBL] [Abstract][Full Text] [Related]
39. Evidence of long-term suppression of hepatitis B virus DNA by tenofovir as rescue treatment in patients coinfected by HIV.
Quiros-Roldan E; Calabresi A; Lapadula G; Tirelli V; Costarelli S; Cologni G; Zaltron S; Puoti M; Carosi G; Torti C
Antivir Ther; 2008; 13(3):341-8. PubMed ID: 18572746
[TBL] [Abstract][Full Text] [Related]
40. Tenofovir: what have over 1 million years of patient experience taught us?
Pozniak A
Int J Clin Pract; 2008 Aug; 62(8):1285-93. PubMed ID: 18705824
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
